e-learning
resources
Stockholm 2002
Monday 16.09.2002
Combination therapies in asthma and COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Specific immunotherapy efficiency along with the flixothide (fluticosan propionate) therapy for patients suffering from bronchial asthma
O. V. Koretska, L. V. Gribanova, I. A. Rodkina (Dnepropetrovsk, Ukraine)
Source:
Annual Congress 2002 - Combination therapies in asthma and COPD
Session:
Combination therapies in asthma and COPD
Session type:
Poster Discussion
Number:
2390
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. V. Koretska, L. V. Gribanova, I. A. Rodkina (Dnepropetrovsk, Ukraine). Specific immunotherapy efficiency along with the flixothide (fluticosan propionate) therapy for patients suffering from bronchial asthma. Eur Respir J 2002; 20: Suppl. 38, 2390
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Specific immunotherapy in grass-pollen allergic asthma combinated with inhaled steroid therapy
vs
specific immunotherapy allone
Source: Eur Respir J 2001; 18: Suppl. 33, 431s
Year: 2001
Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond
Source: Eur Respir J 2006; 28: Suppl. 50, 440s
Year: 2006
Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline
Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges
Year: 2009
Omalizumab therapy of the children with uncontolled atopic bronchial asthma (BA)
Source: Annual Congress 2010 - Clinical aspects and treatment of asthma and allergic respiratory diseases
Year: 2010
Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Efficacy of the long-term therapy with simbicort in children with bronchial asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 395s
Year: 2005
Endotypes of severe allergic asthma patients who clinically benefit from Anti-IgE therapy
Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD
Year: 2018
The effectiveness of nebulizer therapy in the treatment of patients with bronchial asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 424s
Year: 2001
Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009
Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 203s
Year: 2003
Neuroregulatorial therapy of bronchial asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 55s
Year: 2002
Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms
Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Year: 2007
Efficacy of symbicort administration in patients with bronchial asthma
Source: Annual Congress 2009 - Treatment of airways disease
Year: 2009
Efficacy of bronchial thermoplasty (BT) in patients with severe asthma: the AIR2 trial
Source: Annual Congress 2009 - Persistent asthma: still an uncontrolled disease requiring new treatments strategies in 2009
Year: 2009
Assessment of maximal airway response before and after inhaled corticosteriod treatment in new diagnosed asthma patients
Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Year: 2007
Immunotherapy in severe asthma
Source: ERS webinar 2021: Immunotherapy in severe asthma
Year: 2021
Immunological effectiveness of N-acetylcystein in complex therapy in severe persistent bronchial asthma patients
Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma
Year: 2008
Systemic steroid use in children with allergic (IgE-mediated) asthma receiving omalizumab
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010
Combined therapy of severe osteoporosis for patients with bronchial asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 47s
Year: 2001
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept